** Shares of drug developer Regenxbio RGNX.O fall 8.32% to $8.38
** Co posts Q4 loss of $1.30 per share, versus loss of $1.01 per share a year ago. Analysts were expecting a loss of 96 cents per share, according to data compiled by LSEG
** Posts Q4 revenue of $30.3 million, below analysts' estimate of $36.6 million
** R&D expenses for the quarter were $59.6 million, due to higher clinical trial expenses and manufacturing-related costs - RGNX
** RGNX shares had risen over 86% in 2025
(Reporting by Kunal Das in Bengaluru)
((Kunal.Das2@thomsonreuters.com;))
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments